Shots:

• The EMA has granted approval to conduct the P-I basket study of JK06 (FIC quadrivalent, biparatopic ADC) for the treatment of various solid tumors expressing 5T4
• The P-I will be an open-label, dose-escalation & expansion trial to evaluate the safety, pharmacokinetics & preliminary efficacy among 155 individuals (expected). It will be initiated during Q3’24
• JK06 works by targeting 5T4 with an MMAE payload. It showed picomolar affinity, quick internalization, strong efficacy as well as a favorable safety profile in preclinical studies